Drugs / Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03332095 | Jul 2018 → Aug 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03332095 ↗ |
| Known as | DOR/3TC/TDF | “Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)” NCT03332095 ↗ |
| Route | Oral | “DOR/3TC/TDF administered orally as a fixed-dose combination” NCT03332095 ↗ |